These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 33186617)
1. Long-Term Results of NRG Oncology/RTOG 0321: A Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiation Therapy for Adenocarcinoma of the Prostate. Hsu IC; Rodgers JP; Shinohara K; Purdy J; Michalski J; Roach M; Vigneault E; Ivker RA; Pryzant RM; Kuettel M; Taussky D; Gustafson GS; Raben A; Sandler HM Int J Radiat Oncol Biol Phys; 2021 Jul; 110(3):700-707. PubMed ID: 33186617 [TBL] [Abstract][Full Text] [Related]
2. Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321. Hsu IC; Bae K; Shinohara K; Pouliot J; Purdy J; Ibbott G; Speight J; Vigneault E; Ivker R; Sandler H Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):751-8. PubMed ID: 20207506 [TBL] [Abstract][Full Text] [Related]
3. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate. Lawton CA; Yan Y; Lee WR; Gillin M; Firat S; Baikadi M; Crook J; Kuettel M; Morton G; Sandler H Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e795-801. PubMed ID: 22330999 [TBL] [Abstract][Full Text] [Related]
4. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer. Mohammed N; Kestin L; Ghilezan M; Krauss D; Vicini F; Brabbins D; Gustafson G; Ye H; Martinez A Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):204-12. PubMed ID: 21167653 [TBL] [Abstract][Full Text] [Related]
5. Phase II trial of radiation dose escalation with conformal external beam radiotherapy and high-dose-rate brachytherapy combined with long-term androgen suppression in unfavorable prostate cancer: feasibility report. Valero J; Cambeiro M; Galán C; Teijeira M; Romero P; Zudaire J; Moreno M; Ciérvide R; Aristu JJ; Martínez-Monge R Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):386-92. PubMed ID: 19427741 [TBL] [Abstract][Full Text] [Related]
6. A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526). Crook JM; Zhang P; Pisansky TM; Trabulsi EJ; Amin MB; Bice W; Morton G; Pervez N; Vigneault E; Catton C; Michalski J; Roach M; Beyer D; Jani A; Horwitz E; Donavanik V; Sandler H Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):335-343. PubMed ID: 30312717 [TBL] [Abstract][Full Text] [Related]
7. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer. Pellizzon AC; Nadalin W; Salvajoli JV; Fogaroli RC; Novaes PE; Maia MA; Ferrigno R Radiother Oncol; 2003 Feb; 66(2):167-72. PubMed ID: 12648788 [TBL] [Abstract][Full Text] [Related]
8. High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer. Patel S; Demanes DJ; Ragab O; Zhang M; Veruttipong D; Nguyen K; Park SJ; Marks L; Pantuck A; Steinberg M; Kamrava M Brachytherapy; 2017; 16(2):299-305. PubMed ID: 27965117 [TBL] [Abstract][Full Text] [Related]
9. Outcomes Associated With 3 Treatment Schedules of High-Dose-Rate Brachytherapy Monotherapy for Favorable-Risk Prostate Cancer. Jawad MS; Dilworth JT; Gustafson GS; Ye H; Wallace M; Martinez A; Chen PY; Krauss DJ Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):657-66. PubMed ID: 26797541 [TBL] [Abstract][Full Text] [Related]
10. Long-Term Efficacy and Toxicity of Low-Dose-Rate ¹²⁵I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate Cancer. Kittel JA; Reddy CA; Smith KL; Stephans KL; Tendulkar RD; Ulchaker J; Angermeier K; Campbell S; Stephenson A; Klein EA; Wilkinson DA; Ciezki JP Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):884-93. PubMed ID: 25962627 [TBL] [Abstract][Full Text] [Related]
11. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity. Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838 [TBL] [Abstract][Full Text] [Related]
12. High-dose-rate brachytherapy with two or three fractions as monotherapy in the treatment of locally advanced prostate cancer. Hoskin P; Rojas A; Ostler P; Hughes R; Alonzi R; Lowe G; Bryant L Radiother Oncol; 2014 Jul; 112(1):63-7. PubMed ID: 25018002 [TBL] [Abstract][Full Text] [Related]
13. Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. Michalski JM; Moughan J; Purdy J; Bosch W; Bruner DW; Bahary JP; Lau H; Duclos M; Parliament M; Morton G; Hamstra D; Seider M; Lock MI; Patel M; Gay H; Vigneault E; Winter K; Sandler H JAMA Oncol; 2018 Jun; 4(6):e180039. PubMed ID: 29543933 [TBL] [Abstract][Full Text] [Related]
14. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial. Martinez AA; Kestin LL; Stromberg JS; Gonzalez JA; Wallace M; Gustafson GS; Edmundson GK; Spencer W; Vicini FA Int J Radiat Oncol Biol Phys; 2000 May; 47(2):343-52. PubMed ID: 10802358 [TBL] [Abstract][Full Text] [Related]
15. External Beam Radiation Therapy (EBRT) and High-Dose-Rate (HDR) Brachytherapy for Intermediate and High-Risk Prostate Cancer: The Impact of EBRT Volume. Tharmalingam H; Tsang Y; Choudhury A; Alonzi R; Wylie J; Ahmed I; Henry A; Heath C; Hoskin PJ Int J Radiat Oncol Biol Phys; 2020 Mar; 106(3):525-533. PubMed ID: 31610249 [TBL] [Abstract][Full Text] [Related]
16. A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional external-beam radiotherapy for localized prostate adenocarcinoma : a report on acute toxicity. Norkus D; Miller A; Kurtinaitis J; Haverkamp U; Popov S; Prott FJ; Valuckas KP Strahlenther Onkol; 2009 Nov; 185(11):715-21. PubMed ID: 19899003 [TBL] [Abstract][Full Text] [Related]
17. High-dose-rate iridium-192 afterloading therapy combined with external beam radiotherapy for T1c-T3bN0M0 prostate cancer. Jo Y; Hiratsuka J; Fujii T; Takenaka A; Fujisawa M Urology; 2004 Sep; 64(3):556-60. PubMed ID: 15351592 [TBL] [Abstract][Full Text] [Related]
18. Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer. Ghadjar P; Oesch SL; Rentsch CA; Isaak B; Cihoric N; Manser P; Thalmann GN; Aebersold DM Radiat Oncol; 2014 May; 9():122. PubMed ID: 24885327 [TBL] [Abstract][Full Text] [Related]
19. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial. Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182 [TBL] [Abstract][Full Text] [Related]
20. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer. Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]